Last updated: September 30, 2024
Sponsor: Takeda
Overall Status: Completed
Phase
N/A
Condition
Circulation Disorders
Williams Syndrome
Stress
Treatment
Azilsartan (TAK-536)
Clinical Study ID
NCT05107960
TAK-536-4001
jRCT2031210414
Ages 6-15 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria
Participants aged 6 years or older and less than 16 years
Participants with hypertension
Exclusion Criteria Participants with contraindications to azilsartan.
Study Design
Total Participants: 5
Treatment Group(s): 1
Primary Treatment: Azilsartan (TAK-536)
Phase:
Study Start date:
December 16, 2021
Estimated Completion Date:
August 31, 2024
Connect with a study center
Takeda selected site
Tokyo,
JapanSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.